A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF A 200-MCG DOSE OF IPP-201101 PLUS STANDARD OF CARE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: